Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy PipelineProceeds to advance three late-stage programs towards registration, prepare for commercialization and progress the company’s gene therapy platform
BOSTON and LONDON, August 13, 2018-- Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.